Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntelligent Ultrasound Regulatory News (IUG)

  • This share is currently suspended. It was suspended at a price of 12.875
  • There is currently no data for IUG

Form 8.5 (EPT/NON-RI)

11 Feb 2025 08:58

RNS Number : 6805W
Cavendish Securities PLC
11 February 2025
 

FORM 8.5 (EPT/NON-RI)

 

 

 

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cavendish Securities plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Intelligent Ultrasound Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Intelligent Ultrasound Group plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10/02/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

ORD 1P

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

94923

 

0.03

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

94923

 

 

0.03

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 1P

 

 

Sales

 

7

12.997

 

 

 

12.997

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

11/02/2025

Contact name:

Umika Patel

Telephone number:

+44 (0) 0207 220 0594

 

 

 

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOUAVWRVBUUARR
Date   Source Headline
16th Aug 20247:00 amRNSExercise of Options and Total Voting Rights
14th Aug 20247:00 amRNSHalf-year Report
6th Aug 202411:22 amRNSResult of General Meeting
31st Jul 20247:00 amRNSNotice of Results
18th Jul 20248:19 amRNSProposed sale of Clinical AI Business for £40.5m
18th Jun 20244:54 pmRNSResult of AGM
23rd May 20247:00 amRNSNotice of AGM and 2023 Report and Accounts
7th May 20244:20 pmRNSHolding(s) in Company
1st May 20247:00 amRNSFinal Results
19th Apr 20247:00 amRNSSonolyst launched on Voluson Signature Series
19th Apr 20247:00 amRNSNotice of Results
29th Feb 20247:00 amRNSNHS Scotland Adopts Classroom to Clinic Training
27th Feb 20243:45 pmRNSScanNav FetalCheck Used in Trial Study
9th Feb 20247:00 amRNSLaunch of Portable NeedleTrainer Plus
9th Jan 20247:00 amRNSTrading Update
22nd Dec 20237:00 amRNSGrant of Share Options
27th Nov 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
23rd Nov 20237:00 amRNSLaunch of ScanNav FetalCheck and its use in study
17th Nov 20237:00 amRNSSonoLystlive now standard on Voluson Expert Series
7th Nov 20237:00 amRNSIntelligent Ultrasound signs research agreement
11th Sep 20237:00 amRNSSonoLystlive launched on Voluson Expert Series
17th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
24th Jul 20237:00 amRNSTrading Update
21st Jun 20234:08 pmRNSResult of AGM
26th May 20237:00 amRNSDirectorate Change
26th May 20237:00 amRNSNotice of AGM and 2022 Report and Accounts
22nd May 20233:57 pmRNSHolding(s) in Company
18th May 20237:00 amRNSMello investor conference
20th Apr 20233:15 pmRNSHolding(s) in Company
20th Apr 20237:00 amRNSFinal Results
23rd Mar 20234:45 pmRNSPDMR/PCA Dealing
15th Mar 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSTrading update
8th Dec 20227:00 amRNSSupport programme in improving global healthcare
30th Nov 20221:12 pmRNSResult of GM
11th Nov 20227:00 amRNSPlacing and Subscription to raise £5.2 million
20th Oct 20227:00 amRNSScanNav Anatomy PNB clearance for sale in the USA
19th Oct 20222:05 pmRNSSecond Price Monitoring Extn
19th Oct 20222:00 pmRNSPrice Monitoring Extension
23rd Sep 20227:00 amRNSChange of Auditor
2nd Sep 202211:09 amRNSLaunch of NeedleTrainer 2
18th Aug 20227:00 amRNSHalf-year Report
15th Aug 20227:00 amRNSDirectorate Change
8th Aug 20227:00 amRNSNotice of Results
21st Jul 20227:00 amRNSTrading update
20th Jul 20227:00 amRNSAI technology incorporated into Voluson Expert 22
22nd Jun 202212:08 pmRNSResult of AGM
22nd Jun 20227:00 amRNSAGM Statement
21st Jun 202211:05 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.